- Home
- III vs YMAB Comparison
III vs YMAB Comparison
Compare III & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- III
- YMAB
- Stock Information
- Founded
- III 2006
- YMAB 2015
- Country
- III United States
- YMAB United States
- Employees
- III N/A
- YMAB N/A
- Industry
- III Professional Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- III Consumer Discretionary
- YMAB Health Care
- Exchange
- III Nasdaq
- YMAB Nasdaq
- Market Cap
- III 227.5M
- YMAB 192.4M
- IPO Year
- III 2007
- YMAB 2018
- Fundamental
- Price
- III $4.81
- YMAB $4.36
- Analyst Decision
- III Buy
- YMAB Buy
- Analyst Count
- III 1
- YMAB 11
- Target Price
- III $5.50
- YMAB $17.55
- AVG Volume (30 Days)
- III 227.1K
- YMAB 202.0K
- Earning Date
- III 08-06-2025
- YMAB 08-11-2025
- Dividend Yield
- III 3.72%
- YMAB N/A
- EPS Growth
- III N/A
- YMAB N/A
- EPS
- III 0.16
- YMAB N/A
- Revenue
- III $242,899,000.00
- YMAB $88,658,000.00
- Revenue This Year
- III N/A
- YMAB N/A
- Revenue Next Year
- III $5.08
- YMAB $15.15
- P/E Ratio
- III $30.91
- YMAB N/A
- Revenue Growth
- III N/A
- YMAB 4.92
- 52 Week Low
- III $2.95
- YMAB $3.55
- 52 Week High
- III $5.28
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- III 50.05
- YMAB 45.29
- Support Level
- III $4.98
- YMAB $4.10
- Resistance Level
- III $5.28
- YMAB $4.62
- Average True Range (ATR)
- III 0.17
- YMAB 0.29
- MACD
- III 0.00
- YMAB -0.04
- Stochastic Oscillator
- III 37.33
- YMAB 20.73
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.